about
V. Molecular classification and risk stratification of myelomaThe proto-oncogene BCL-6 in normal and malignant B cell developmentHypermethylation of gene promoters in hematological neoplasiaNatural killer cell lymphoma/leukemia: pathology and treatmentReal-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemiaThe cut-off levels of CD23 expression in the differential diagnosis of MCL and CLLAcute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patientsCandidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis.Lymphoma at uncommon sites.Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.FDG-PET/CT is a pivotal imaging modality to diagnose rare intravascular large B-cell lymphoma: case report and review of literature.Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data.Agnogenic myeloid metaplasia (AMM)--correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients.ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma.The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin.Current and future use of hematopoietic growth factors in cancer medicine.Chronic myelomonocytic leukemia: lost in classification?Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea.Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Successful treatment of non-Hodgkin lymphoma associated immune thrombocytopenia with involved field radiotherapy.The myelotoxicity of carboplatin is influenced by the time of its administration.Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series.Absent clinical effects of retinoic acid and isoretinoin treatment in the myelodysplastic syndrome.Risk of hemophagocytic lymphohistiocytosis in adults with fevers of unknown origin: the clinical utility of a new scoring system on early detection.Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.A comparison of bone marrow findings in patients with acquired immunodeficiency syndrome (AIDS) and AIDS related conditions.Mediastinal germ cell tumour associated with malignant histiocytosis and high rubella titres.Long lasting lymphadenopathy in childhood as an expression of a severe hyperimmune B lymphocyte disorder.Solid tumour with initial presentation in the bone marrow--a clinicopathologic study of 25 adult cases.Recent advances in the management of myelodysplastic syndromes.A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphom
P1433
Q26861396-69819C90-D69A-4C30-9166-CD03AAADE88CQ28216775-FBD8F9FA-0375-4DCB-B42C-8B624193CE92Q28216777-014D3A74-3254-4D1E-A5A6-44AB74D9D3B1Q28255081-43755423-75B2-47DF-9E59-6F91536C0645Q28257512-FA7BBE9A-0764-4824-A5C5-737DCECE1207Q28274788-0D0F2154-720A-4072-8D75-48A48FF240D2Q28286577-DAB7290A-D91E-4197-85E3-4D2F752F037FQ30252147-9BF9AD4F-2FC4-452E-A1EB-9C989AFB86C1Q30791699-BD9DC475-7977-4A0A-A888-F9496201446DQ30801095-B9C5AEA3-0A1B-4765-8C9F-C27A30719AC8Q30825337-291C66D3-C679-45A5-9287-0C1AFD03BC45Q31131542-2B22A5F7-6B22-4D77-8A66-D88AF3D99CFCQ31133393-DC50D3C1-C37E-4284-A292-7760AA60420EQ33194244-CC1BEE39-8B18-418E-9F3A-29800518246CQ33260709-3F9D82AD-03E5-41C5-B504-A193F6296897Q33268051-6B5FCD24-7CC1-4F06-AF89-0F48AC887C3BQ33343175-7F687A94-0BD6-4E67-BFD2-2F7F5A96D361Q33367026-C7DA48F1-8CA3-4F37-954A-E0F14219C97EQ33368341-403781C9-20D8-44D1-A13A-4D24E90A38FDQ33372559-3CDF20AB-BF3D-440E-AE83-647492C1B080Q33375157-4D5B4934-6CE0-4AA9-B1CA-EA7D056852E5Q33375317-FA1265A0-C308-432B-8E6D-4626D65399B3Q33388653-B1E28585-251A-4E4E-864B-D95E41A1FEF0Q33404090-BBD7517A-0257-49CA-8409-06058028A395Q33407189-EA305A67-A6E7-49F3-8351-CEA0D740FE05Q33410441-2C8BAC0E-A852-4D30-8429-1C36AF7535D0Q33416982-B120A0A1-4C2E-45C2-A263-FB36B640E44EQ33420118-A3D64E47-9492-48FA-87CB-6E63C2989F08Q33433613-9FE7B368-2765-4C7A-960B-FA1D9002B294Q33434216-3C5018A1-9A07-4511-AA12-FD6FFE662A53Q33441641-9E79AA66-E0D2-434E-B57D-40F63ED51C9CQ33441917-1AED1554-1380-43C2-ABCC-CDAF33954BEEQ33442798-810FC48A-1E0C-4D15-A6C2-257406285C1EQ33443417-B7B93A04-0E51-4082-BD0C-2C3D5C492FA6Q33452659-37405D85-499E-414C-A59B-C47550B37E4DQ33456427-01AEFDC8-6B91-4C57-BD8B-FD32C32D53D6Q33479919-84883883-380F-45AC-A424-AC8193E97CD0Q33493652-374792D0-2D1B-4609-B621-171BD7D3B1F3Q33494729-8F86190E-CF58-47BE-AF7B-B2B0C53B2093Q33500108-EF450EFF-9EDE-4782-A157-19EE460B69CD
P1433
description
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal
@en
wetenschappelijk tijdschrift van Wiley-Blackwell
@nl
wissenschaftliche Fachzeitschrift
@de
науковий журнал
@uk
مجلة
@ar
name
Hematological Oncology
@ast
Hematological Oncology
@de
Hematological Oncology
@en
Hematological Oncology
@es
Hematological Oncology
@fr
Hematological Oncology
@it
Hematological Oncology
@nl
type
label
Hematological Oncology
@ast
Hematological Oncology
@de
Hematological Oncology
@en
Hematological Oncology
@es
Hematological Oncology
@fr
Hematological Oncology
@it
Hematological Oncology
@nl
prefLabel
Hematological Oncology
@ast
Hematological Oncology
@de
Hematological Oncology
@en
Hematological Oncology
@es
Hematological Oncology
@fr
Hematological Oncology
@it
Hematological Oncology
@nl
P3181
P356
P1055
P1058
P1156
P123
P1250
P1277
P1476
Hematological Oncology
@en
P236
P3181
P356
10.1002/(ISSN)1099-1069